Creating new pain relief medications that target LPA5 receptors
Development of LPA5 Antagonists as Analgesics
['FUNDING_OTHER'] · RESEARCH TRIANGLE INSTITUTE · NIH-10638278
This study is looking for new pain relief options for people with nerve pain, like those with nerve injuries or multiple sclerosis, by testing medications that work differently than opioids, aiming to help you manage pain safely without the risk of addiction.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RESEARCH TRIANGLE INSTITUTE (nih funded) |
| Locations | 1 site (RESEARCH TRIANGLE PARK, UNITED STATES) |
| Trial ID | NIH-10638278 on ClinicalTrials.gov |
What this research studies
This research focuses on developing new medications that can effectively relieve neuropathic pain without the risks associated with opioids. It investigates the role of the LPA5 receptor, which is involved in pain processing, particularly in conditions like nerve injury and multiple sclerosis. By blocking this receptor with specific antagonists, the research aims to provide safer alternatives for pain management. Patients may benefit from a new class of analgesics that do not lead to dependence or abuse.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing neuropathic pain due to conditions such as nerve injury or multiple sclerosis.
Not a fit: Patients who do not suffer from neuropathic pain or have other types of pain not related to the LPA5 receptor may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer, non-opioid pain relief options for patients suffering from neuropathic pain.
How similar studies have performed: Previous research has shown promise in targeting LPA5 for pain relief, indicating that this approach could be a viable option for developing new analgesics.
Where this research is happening
RESEARCH TRIANGLE PARK, UNITED STATES
- RESEARCH TRIANGLE INSTITUTE — RESEARCH TRIANGLE PARK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHANG, YANAN — RESEARCH TRIANGLE INSTITUTE
- Study coordinator: ZHANG, YANAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.